Alipay Supports Xi’an to Build “International Consumer Friendly Tourist Destination”
24.5.2024 14:15:00 EEST | Business Wire | Press release
Alipay, the leading digital payment and lifestyle service platform, today announced that it is working with Xi’an, the world-renowned ancient capital city located in Shaanxi province famous for the Terracotta Warriors, to launch the “International Consumer Friendly Tourist Destination” initiative. With the resurgence of inbound tourism to China, the initiative aims to enhance the travel and shopping experiences of international visitors to Xi’an and boost the city’s tourism industry.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240524320945/en/
Launch ceremony of “International Consumer Friendly Tourist Destination” Xi’an (Photo: Business Wire)
Alipay – with the support and guidance of local authorities – is working with its partners in Xi’an, including tourist attractions, hotels, restaurants, and public transit agencies, to upgrade their payment and digital services for international travelers.
International visitors can now link their international Visa, Mastercard, JCB, Discover®, or Diners Club International® credit or debit card in the Alipay app to easily pay at a wide range of Chinese mainland merchants in the Alipay merchant network.
In addition to paying like a local with Alipay, international tourists can also use their home e-wallet while exploring China. These e-wallets include AlipayHK (Hong Kong SAR, China), MPay (Macao SAR, China), Touch ’n Go eWallet (Malaysia) and Kakao Pay (South Korea), Hipay (Mongolia), Changi Pay (Singapore), OCBC (Singapore), Naver Pay (South Korea), Toss Pay (South Korea), TrueMoney (Thailand), NayaPay (Pakistan), and Kaspi.kz (Kazakhstan).
Following the successful introduction of digital red packets, which international tourists could claim by scanning a QR code at Mount Huangshan before the May Day holiday in 2024, Alipay is expanding the service. Effective immediately through June 30, international travelers in Xi’an can claim digital red packets for discounts on offline purchases throughout China. Participating merchants include tourist attractions such as Tang Paradise and the Longest Day in Chang'an Theme Block, Lanxiangzi and other chain restaurants, Chahuanong and other tea brands, and food streets like Yongxing Fang, as well as metro and bus stations.
According to Alipay statistics, the transaction volume of international visitors using Alipay in Xi’an has increased by nearly seven times in the first four months of 2024, compared to the same period last year. The data showed that the top ten tourist attractions that international visitors pay through Alipay are: the Great Tang All Day Mall, Tang Paradise, Emperor Qinshihuang's Mausoleum Site Museum, Mount Huashan, Bell and Drum Tower, Daming Palace National Heritage Park, Huaqing Palace, Tang West Market Museum, Yongxing Fang, and the Hancheng Lake Scenic Area.
Alipay provides global tourists with a convenient and secure mobile payment service and various travel services to enhance their travel experience in China through collaboration with industry partners. Accessible directly from Alipay's homepage, these easy-to-access services include online translation, ride-hailing services, public transport, hotel reservations, and train ticket bookings.
“Alipay looks forward to working with even more partners to enhance the payment and travel experience for both domestic and international tourists. We aim to support an increasing amount of local tourist attractions and commercial districts to create a travel and shopping experience that is welcoming to visitors from all around the world,” said Jiajia Li, vice president of Alipay business group at Ant Group.
About Alipay
In the digital era, Alipay has evolved from a trusted payment tool to an open platform that connects businesses, institutions, service providers, and other partners with consumers. Alipay enables partners from various industries to offer safe and convenient payment options. It also enables partners to communicate and deliver different digital services to their customers in China through Alipay mini programs, lifestyle accounts and other tools. The Alipay platform has connected over 80 million businesses with more than one billion consumers.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240524320945/en/
Contact information
Media Inquiries
Bell Wang
yixing.wl@antgroup.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
From Network Automation to Agentic NetOps: NetBrain Sets the Standard for Deploying AI in Network Operations29.5.2026 16:00:00 EEST | Press release
NetBrain Technologies, Inc. today announced major new platform features that advance Agentic NetOps from an emerging category to operational reality. NetBrain's clients are already deploying agents that are diagnosing and remediating issues across complex multi-vendor enterprise networks. These new features further extend the platform with new agent tooling, cross-domain context, and open interfaces for the broader agentic enterprise. Early customer outcomes show the magnitude of the shift: A leading health insurer used NetBrain's Deep Diagnosis agent to diagnose and resolve a weeks old VPN connectivity issue in under five minutes. A large manufacturer resolved a critical device issue with a single prompt, isolating the root cause across the network path in under 20 minutes, saving hundreds of hours of engineer time, shrinking MTTR by more than 95%. A global telecommunications firm found NetBrain's context-grounded agents outperformed a stand-alone frontier LLM on a persistent firewall
Adtran resolves long-running patent litigation, reinforcing commitment to defend innovation29.5.2026 15:00:00 EEST | Press release
Adtran today announced it has resolved a patent litigation matter, resulting in a full settlement and dismissal of all claims with prejudice. The case, initiated in 2020 by a non-practicing entity asserting five patents, was transferred to the US District Court for the Northern District of Alabama in 2021 following a successful motion by Adtran. Adtran subsequently filed counterclaims, including bad-faith patent assertion under Alabama statutory law. The settlement includes payment to Adtran to resolve its counterclaims. Terms of the agreement remain confidential. “This outcome reflects a disciplined and consistent approach to protecting our innovation and our customers,” said Justin Ferguson, SVP and general counsel at Adtran. “We take all claims seriously, but we will not hesitate to defend ourselves when assertions lack merit. Situations like this place unnecessary strain on technology providers and divert resources from advancing networks and services. By advancing our counterclaim
Meiji Seika Pharma Invests in GHIC’s Global Health Security Fund29.5.2026 14:00:00 EEST | Press release
Meiji Seika Pharma Co., Ltd. (Headquarters: Tokyo, Japan; President and Representative Director: Toshiaki Nagasato) today announced that it has committed to invest in the Global Health Security Fund (GHSF), which is sponsored by Global Health Investment Corporation (GHIC), a New York-based nonprofit organization. Through this investment, Meiji Seika Pharma will support the acceleration of innovations addressing critical global health challenges, including pandemic preparedness and antimicrobial resistance (AMR). GHIC is a mission‑driven nonprofit organization that deploys private investment strategies to generate both global health impact and financial returns. GHIC recently closed its second fund in GHSF. With more than a decade of experience investing in the field of infectious disease, GHIC has contributed to addressing major global health challenges. Its portfolio companies have successfully commercialized more than a dozen products, collectively reaching over 600 million people wo
IFF Enters Into Agreement to Sell Its Food Ingredients Business to CVC29.5.2026 13:50:00 EEST | Press release
IFF (NYSE: IFF), a global leader in flavors, fragrances, food ingredients, and health and biosciences, today announced that it has entered into an agreement to sell its Food Ingredients business to funds advised by CVC Capital Partners, a leading global private markets manager, in a transaction that values the business at approximately $4.3 billion, representing an enterprise value-to-EBITDA multiple of approximately 10x. As part of the transaction, IFF has chosen to retain an approximately 10% minority equity interest in the business, or approximately $200 million, permitting continued collaboration and cooperation between IFF and Food Ingredients and allowing IFF and its shareholders to participate in future value creation under its new ownership. The transaction marks a significant step in IFF’s portfolio transformation and is expected to strengthen the company’s focus on its innovation-driven businesses: Taste, Scent, and Health & Biosciences. Following the transaction, IFF will be
BeOne Medicines Establishes Standard for Long-Term Disease Control in CLL with BRUKINSA 78-Month Data at ASCO 202629.5.2026 13:00:00 EEST | Press release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, is advancing the treatment paradigm in chronic lymphocytic leukemia (CLL) at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting. With extensive long-term follow-up, the SEQUOIA study of BRUKINSA® (zanubrutinib) reinforces its role as the foundational BTK inhibitor, showing sustained disease control over years of therapy. These findings are further supported by real-world evidence across three large analyses encompassing more than 250,000 patients, underscoring consistent effectiveness and safety in clinical practice. Additionally, BEQALZI™ (sonrotoclax), which was recently approved by the U.S. Food and Drug Administration, and its development in combination with BRUKINSA (ZS) highlight the potential for next-generation, time-limited treatment approaches in CLL. Amit Agarwal, M.D., Ph.D., Chief Medical Officer, Hematology, BeOne Medicines, said: “CLL is a disease patients live with
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom